Company Description
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.
Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease.
It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2.
The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018.
The company was incorporated in 2017 and is based in South San Francisco, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jan 31, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 141 |
| CEO | Jason Coloma |
Contact Details
Address: 171 Oyster Point Blvd, Suite 300 South San Francisco, California 94080 United States | |
| Phone | 650 850 5070 |
| Website | mazetx.com |
Stock Details
| Ticker Symbol | MAZE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1842295 |
| CUSIP Number | 578784100 |
| ISIN Number | US5787841007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. | Chief Executive Officer and Director |
| Dr. Harold S. Bernstein M.D., Ph.D. | President of Research and Development and Chief Medical Officer |
| Matt Krause | Senior Vice President of Human Resources |
| Atul Dandekar | Chief Strategy and Business Officer |
| Amy Bachrodt | Senior Vice President of Finance |
| Nazila Habibizad | Senior Vice President of Technical Operations and Supply Chain |
| Maarten Hoek | Senior Vice President of Research |
| Winston Tse | Senior Vice President of Drug Discovery |
| Susan Limb | Senior Vice President of Clinical Development |
| Andrew Good | Vice President and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | ARS | Filing |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 22, 2026 | 8-K | Current Report |
| Apr 22, 2026 | 424B5 | Filing |
| Apr 1, 2026 | SCHEDULE 13G | Filing |
| Mar 30, 2026 | 144 | Filing |
| Mar 25, 2026 | 10-K | Annual Report |
| Mar 25, 2026 | 8-K | Current Report |
| Mar 10, 2026 | 144 | Filing |